Table 2.

Dermatological drug adverse events.

Drug	Adverse events	Prevalence/comments
Thiopurines	Skin and soft tissue infection Non-melanoma skin cancer Drug hypersensitivity Shingles	Frequently cellulitis Patient education, sun protection, and routine annual skin check important Prevalence up to 10%377 Patients aged > 60 years treated in combination with systemic corticosteroids are at higher risk 378,379
Anti TNF	Skin reactions Drug-induced lupus erythematosus [DILE] Skin and soft-tissue infection Melanoma Paradoxical skin reactions: eczema-like, psoriasis-like	Subcutaneous injection site reaction and delayed infusion reaction 380 Rare; no class effect 381 Cellulitis, erysipelas, abscess [0.1% to 7%] 382,383 Slight increased risk 382,383,384 Psoriasis: pustular phenotype [commonly palms and soles]; eczema: atopic diathesis 385,386
Sulfasalazine	Exfoliative dermatitis, StevensJohnson syndrome, and toxic epidermal necrolysis	Rare but serious skin reactions, some fatal; discontinue drug if skin or mucosal lesion387
Methotrexate	Alopecia Generalised skin rash Oral and intertriginous lesions	< 10%; more common long term Less frequent than reported Rare; consider drug over-dosage [daily instead of weekly]388
Vedolizumab	Infusion-related and hypersensitivity reactions Rash, pruritus, eczema, acne	Requires previous antihistamine, hydrocortisone. and/ or paracetamol389